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Since the first report on the serodiagnosis of HIV-1  
infection in 1987, several laboratories from India have 
contributed significantly to the knowledge of HIV/ 
AIDS over the years. These reports span a wide range 
of disciplines including serological and molecular 
characterization of the viral strains circulating in  
India; elucidation and characterization of the recom-
binant strains; study of the economic impact of the  
viral infection; examination of the immune profile of 
the host; delineating the natural history of HIV-1/ 
AIDS; evaluation of the awareness among general 
populations; molecular validation of the primary viral 
isolates and study of their pathogenic properties in-
cluding neuro-pathogenesis; developing and evaluat-
ing alternative therapeutic strategies for HIV/AIDS; 
vaccine development and validation in human clinical 
trials, etc. The quantum of academic research in India 
is driven mainly by individual investigators affiliated 
to research institutions, universities and clinics spread 
across the country, with a few research institutes and 
non-government organizations making significant 
contributions. Given the space restriction and the  
volume of the research that has appeared in peer-
reviewed journals, it would not be possible to encom-
pass all this work in the present review. This review 
primarily focuses on a few basic and application-
oriented research reports that appeared over the 
years from India. Additionally, attention will be 
drawn to several other elegantly written reviews that 
focused on areas that have not been covered here.  
 
Keywords: HIV/AIDS, seroconverters, viral infection, 
viral molecular epidemiology. 
Viral molecular epidemiology  
IN India, since the first report of HIV infection in 1987 
(ref. 1), the rate of viral incidence and prevalence remai-
ned low and stable over the years. According to the  
National AIDS Control Organization (NACO), the over-
all viral prevalence among general adult population of 
India remains at 0.36% as of 2006 which translates to  
approximately 2.5–3.0 million cases. Although the rea-
sons for significantly low levels of viral incidence in  
India as compared to African countries, where subtype C 
is also the predominating strain, are not completely un-
derstood, socio-economic conditions, cultural factors, 
host genetics and family traditions may have played or 
are playing an important role. Of note, among the high-
risk groups, including injecting drug users (IDU), men 
who have sex with men (MSM) and female sex workers 
(FSW), the infection rates are higher than 5% (NACO, 
India), suggesting that host resistance may have a limited 
significance. Although India harbours the second largest 
number of HIV infections in the world, the number of 
scientific studies and research publications appearing 
from India rather remains small and inadequate.  
 The topic of molecular epidemiology and distribution 
of diverse viral subtypes in India has been reviewed  
earlier2–8. Lakhashe et al.9 have recently reviewed the 
sentinel surveillance system of India which is mainly  
responsible for the periodical evaluation of seroprevalence 
of HIV-1 infections in India. The molecular nature of the 
HIV-1 strains in circulation in India, the magnitude of 
genetic variations among the circulating viral strains, and 
the implications of such genetic variations for drug resi-
stance and control measures have been reviewed9–11. The 
present review will attempt at highlighting a few unique 
characteristics of the HIV-1 infections in India. A few  
research publications that appeared during the past one or 
two years will also be discussed.  
 Several characteristics of the viral epidemics of India 
are unique and distinct from the epidemics of other coun-
tries. First, the viral epidemics of India by and large have 
been driven primarily by subtype C strains12–17. Although 
over the decades, several non-subtype C strains of group 
M have been reported by several groups, subtype C 
strains have been responsible for viral incidence up to as 
high as 85–99% (refs 12, 18–21). Depending on the phylo-
genetic relatedness of the viral strains of the two coun-
tries, the viral infections of India are believed to have 
been introduced from South Africa22. A limited number 
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of publications suggest further that following the initial 
introduction, the viral strains of India have undergone 
additional genetic variation quite unique for the Indian 
context such that the sequences of the viral genes typi-
cally form a monophyletic cluster23,24. Heterosexual contact 
remains the primary route of entry for HIV in India25–29. 
Second, molecular nature of the viral strains circulating 
in the north-eastern states of India is quite distinct from 
that of the mainland India and forms the second focus of 
the viral epidemics. These strains are spread mainly 
through drug abuse and are phylogenetically related to the 
subtype B viral strains of Myanmar and China12,13,27,30. 
Third, several non-subtype C viral strains have been re-
ported from different parts of India12,15,18–20,31–37. Subtype 
A appears to be most common among such strains closely 
followed by subtype B viruses and additionally, with sub-
types D and A/E also documented. Despite the regular 
appearance of the non-subtype C strains and the reporting 
by several groups, it is not clear why these viral strains 
do not seem to initiate their own epidemics and infection 
foci in India. Fourth, a large number of publications re-
ported the presence of recombinant viruses from different 
regions of India. These publications have been reviewed 
recently11. Most of these studies are not only limited in 
sample size but also a lack of follow up of the findings 
makes it unrealistic to estimate the real incidence of the 
recombinants in circulation. Given the regularity and 
generality with which the recombinant viruses have been 
identified by several groups and the extensive variation of 
the sporadic viral sequences reported, it is rather certain 
that a large number of diverse HIV-1 strains are in circu-
lation in India. Lastly, in addition to HIV-1, infections of 
HIV-2 have been detected from different parts of the 
country. Since the first report in 1991 (ref. 38), a large 
number of publications reported the presence of HIV-2 in 
India. Given that the initial studies primarily used sero-
logical detection for HIV-2 diagnosis, the real incidence 
of the viral infections with HIV-2 alone and dual infec-
tions with both HIV-1 and HIV-2 reported during the 
early phase was perhaps unreliable39–45. Several later 
studies confirmed HIV-2 using different molecular  
approaches46–54. Two different groups from India genera-
ted molecular clones of HIV-2 from primary clinical iso-
lates55,56. The incidence of HIV-2 infection and that of 
coinfections with HIV-1 appears to be rather small. A 
consensus emerged that the HIV-2 strains of India are 
closely related to subtype A phylogenetically. Although 
the presence of HIV-2 in India represents a unique situa-
tion, given the small numbers and the limited expansion 
of this viral group, HIV-2 may not be considered to be a 
significant problem for India.  
 Rao et al.57 recently developed a mathematical model 
to predict the number of people living with HIV/AIDS 
over the next five years period taking into consideration 
targeted interventions among high risk groups, provision 
of anti-retroviral therapy, and behaviour change among 
HIV-positive individuals. Their work identified the 
spread of the viral epidemics in India to be less severe 
compared to the trend observed in the late 1990s. 
Natural history of viral infection in India 
Unlike in the industrialized countries, the Indian HIV 
epidemics are characterized by heavy incidence of several 
opportunistic infections, a situation similar to that of 
various African countries. The most common infections 
associated with AIDS development are pulmonary tuber-
culosis (up to 49%), Pneumocystis carinii pneumonia 
(6%), cryptococcal meningitis (5%), central nervous system 
toxoplasmosis (3%) and cytomegalovirus retinitis, among 
others58–62. Infections of the nervous system have been 
reviewed and tuberculosis followed by cryptococcosis 
and toxoplasmosis in various combinations are the major 
neuropathologies in the Indian clinic6,63,64. Viral infections 
and HIV-associated neoplasia seem to be infrequent, in-
cluding primary CNS lymphomas. HIV encephalitis and 
HIV-associated dementia too are considered infrequent. 
 The excessive parasite and microbial burden is belie-
ved to constitute a constant source of chronic immune  
activation leading to enhanced immune activation markers 
in the normal population of Africa65. A positive correla-
tion between immune activation and the rate of disease 
progression has been observed66 and proposed to be an 
important parameter underlying faster disease progression 
in Africa67, although a difference in the rate of disease pro-
gression between industrialized and low-income countries 
remains highly controversial68. No studies from India  
examined the important association between chronic  
immune activation due to heavy parasite and microbial 
burden, and its influence on the dynamics of disease pro-
gression.  
 Considering the presence of subtype C in India, the ex-
istence of excessive parasite burden and the differences in 
the profile of host-restriction factors including the HLA 
variations, it is of concern whether the rate of disease 
progression in India differs significantly as compared to 
what has been reported from the industrialized nations. 
Unlike in Africa, studies considering important questions 
on natural history of the infection have been scarce from 
India and as a consequence, no clear understanding has 
emerged on any of these important issues.  
 In addition to the problem of inadequate information 
on the viral natural history, the applicability of the CDC 
classification system to the Indian context appears to be 
controversial. In 1993, CDC revised its definition of 
AIDS-related illness by including the CD4 cell count 
drop below 200 cells/μl in addition to including tubercu-
losis, recurring bacterial infections and invasive cervical 
carcinoma69. In the developed countries, CD4 cell dyna-
mics including the absolute numbers, percentage of CD45 
cells and the rate of decline with disease progression play 
an important role as a valuable prognostic marker, although 
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in combination with the viral load70–72. CD4 cell count, 
however, may vary significantly depending on several 
factors including geographic location, ethnic origin, age, 
gender and changes in total and differential leucocyte 
count. The reliance of the CDC classification system on 
the CD4 cell count to fall below 200 cells/μl to predict 
AIDS-related illness has led to serious confusion  
according to its validity in the underdeveloped countries 
including Africa73–75, China76,77 and India78–81. Since the 
baseline CD4 cell count in the healthy individuals could 
have a direct impact on HIV disease progression and the 
dynamics of CD4 cell drop, several research groups  
attempted to determine the ranges of CD4 profile in nor-
mal Indian populations. In one of the largest studies re-
ported from India, a national task force constituted by the 
Indian Council of Medical Research (ICMR), performed  
immunophenotyping by flow cytometry for CD3, CD4, 
CD8, CD19, CD16 and CD56 populations in peripheral 
blood samples from a total of 1027 healthy Indians hail-
ing from different parts of India82. This study did not find 
significant differences in the ranges of several T- and  
B-cell sub-populations tested, with the exception of the 
CD4 cells, in healthy Indians as compared to American 
standards reported previously83. Importantly, this study 
identified significantly low CD4 numbers in the healthy 
populations of the southern Indian states as compared to 
those of the northern and western populations. The vali-
dity of this finding is questionable given that no clinical 
validation of the flow cytometry assays was established 
among the various laboratories that participated in this 
study and additionally different laboratories used differ-
ent antibodies in the analysis. Furthermore, in a different 
study, Kannangai et al.84 from Vellore in southern India 
identified significantly higher CD4 cell numbers (1048 ± 
210 cells/μl) in their clinical cohort as compared to the 
ICMR study. Kannangai et al., however, used a non-
standard assay, the Capcellia CD4/CD8 whole blood  
assay, for the evaluation of the CD4 count in their clinical 
cohort. The reliability and significance of these observa-
tions remain to be ascertained in future studies. Several 
other reports from India too identified relatively low  
levels of CD4 numbers in healthy adult populations as 
compared to the reference standards of the developed 
countries78,80,81,85–87 whereas one report did not88. Many 
of these studies are limited with respect to smaller sample 
size, restricted geographical distribution and less strin-
gent technology employed to measure CD4 cell count.  
 A small number of reports attempted to study the pro-
file of disease progression in India. Mehendele et al.89, in 
a prospective cohort study of 46 drug-naïve recent sero-
converters, determined a median HIV viral load set point 
of 28,729 RNA copies/ml and a corresponding median 
CD4 count of 644 cells/mm3. Interestingly, the study found 
that the initial changes in viral load and CD4 values in 
Indian seroconverters were similar to those of untreated 
HIV-infected seroconverters from a US Multicentric 
AIDS Cohort study of 33,759 RNA copies/ml and 
599 cells/mm3 respectively, at six months from serocon-
version90. Despite these similarities, the study proposed a 
rapid disease progression in the Indian clinical cohort 
with a median decline of CD4 count of 120 CD4 cells/ 
year and a concomitant median early increase in plasma 
viral load of 10.17 log10 RNA copies/ml/year (8274 RNA 
copies/ml/year) during the study period of 720 days. In a 
different study by Ding et al.91 that appeared recently 
from India, the authors failed to find such sharp depletion 
in CD4 cell count with disease progression. Hira et al.92 
detected faster rate of disease progression among the  
heterosexual cohort in Mumbai in a study involving a 
prevalent cohort of 1009 seropositive and drug naïve sub-
jects comprising of 488 asymptomatic, 259 with AIDS-
related complex (ARC), and 262 with AIDS as compared 
to what was reported for homosexual men and haemo-
philiacs of the developed countries93. The study deter-
mined the time taken from the asymptomatic stage to 
ARC, ARC to AIDS using time series analysis and AIDS 
to death using Weibull curves. The median incubation  
periods for progression were found to be 7.9 years for 
HIV to AIDS, 1.9 years for ARC to AIDS and 19.2 
months for the median survival after developing AIDS. 
Kumarasamy et al.94 in a retrospective analysis of 594  
patients in Chennai, southern India, found that the mean 
duration of survival for the study participants was 92 
months from the date of HIV serodiagnosis. This study 
was based only on CD4 cell count and concomitant viral 
load changes have not been studied in disease progres-
sion59. Improved survival among HIV seropositive sub-
jects has been recorded in a clinical cohort by the same 
research group. Singh et al.10 have recently reviewed the 
natural history of HIV infection among children in India. 
Immunology of viral infection  
HIV-1 is a uniquely difficult target to develop immuno-
logical intervention against. In this regard, one of the 
main hindrances has been our lack of understanding as to 
what constitutes protective immunity to the virus. A 
small number of studies from India have focused on  
examining immune response to HIV. Anti-HIV-1-specific 
T cell responses in early HIV-1 infection have been found 
to be important in determining the course of disease pro-
gression. A number of studies have examined cytotoxic T 
cell (CTL) responses in HIV seropositive subjects. In one 
of the first reports from India, Paranjape et al.95 identified 
strong CTL responses to Gag and Nef in recent serocon-
verters. A subsequent report from the same group exten-
ded this work and demonstrated that immune responses 
especially to Gag controlled viral replication in the early 
phase of the infection96. Studies from Delhi in northern 
India indicated that both CD4(+) and CD8(+)T cells dis-
play higher magnitude of immune response to p24/Gag 
with the induction of IFN-γ secretion being significantly 
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higher than that of IL-2 (ref. 97). Studies from Pune, 
western India detected several immunodominant epitopes 
in Gag and Nef proteins of which a few epitopes were 
novel98. A similar study recently has identified additional 
novel epitopes in Gag and Nef proteins99. The identification 
of Gag- and Nef-specific responses across HIV-1 infected 
Indian populations and targeting epitopes from multiple 
immunodominant regions may provide useful insights 
into the designing of new immunotherapy and vaccines. 
 Study of the cytokine dysregulation has been a research 
priority for some of the Indian laboratories. Studies from 
CMC, Vellore in southern India identified a direct corre-
lation between increased levels of plasma interleukin 
(IL)-10 and a rapid fall in CD4 cell count with an associ-
ated disease progression to AIDS100. In a comparative 
analysis from Vellore, plasma IL-10 levels were found to 
be significantly higher among HIV seropositive subjects 
as compared to normal healthy controls21. Furthermore, 
the same study also reported that in this southern Indian 
cohort, IFN-γ levels among symptomatic and AIDS 
groups were significantly elevated as compared to asymp-
tomatic subjects. This study also identified a shift in the 
cytokine profile from Th1 to Th2 with disease progres-
sion similar to what was previously observed in the West. 
In a study from AIIMS, Delhi, northern India, TNF-α 
levels were also found to be higher in HIV seropositive 
subjects as compared to normal healthy controls or  
patients with tuberculosis with wasting101. Wanchu et 
al.102 found that β-2 microglobulin levels in their north-
ern Indian clinical cohort were significantly elevated in 
the viral infection and could be used as a potential marker 
for disease progression. A study from Vellore in southern 
India reported that the mean MIP-1α and RANTES levels 
among the HIV-1 infected individuals were significantly 
higher while those of MIP-1β were lower in their cohort 
as compared to healthy controls103.  
Host and viral factors 
Susceptibility to the viral infection, viral transmission, 
disease progression and response to antiviral therapy all 
have been attributed to variability in multiple host genes 
as well as viral factors. One of the most exciting discov-
eries in the field of HIV-1 infection and progression has 
been the remarkable protection against HIV-1 among  
individuals who were homozygous for CCR5 Δ32 muta-
tion. This deletion common in the USA and the UK is  
extremely rare in India104,105. The promoter regions of 
CCR5 and other chemokine receptors are highly poly-
morphic and haplotype variants possibly accelerating dis-
ease progression of HIV-1 have been reported from the 
All India Institute of Medical Sciences (AIIMS), Delhi in 
northern India106,107. Clearly multiple factors regulate and 
modulate viral proliferation including several cellular 
genes, virus factors, micro-RNAs, HLA antigens, NK-cell 
receptors, etc. A computational prediction by Brahma-
chari’s group at the Institute of Genomics and Integrative 
Biology, Delhi identified several targets for specific  
human miRNAs in the HIV-1 genome108. Subsequent bio-
logical evaluation confirmed that the cellular miRNA, 
hsa-miR29a, interferes with HIV-1 replication by down 
regulating Nef expression from the cell surface109. The 
copy number of the CCL3L1 gene, which exerts a power-
ful influence on disease progression to AIDS, has been 
shown to vary among different regions in the world110. In 
a north Indian clinical cohort, a detailed analysis of the 
variations in several chemokine and chemokine receptor 
genes failed to detect an association between the genetic 
variations studied and susceptibility111. Evidence exists 
that Indian populations preferentially display those HLA 
antigens that support rapid proliferation of the virus112.  
 Several immunomodulatory functions have been ascri-
bed to the HIV-1 accessory protein, Nef, including down 
regulation of CD4, MHC-1 and MHC-II. Shahid Jameel’s 
group at the International Center for Genetic Engineering 
and Biotechnology, Delhi identified a novel immuno-
modulatory function of Nef which possibly contributes to 
viral pathogenesis. Their studies demonstrated a novel 
role for Nef in redistributing the costimulatory molecules 
CD80 and CD86 away from the cell surface in human 
monocytic cells thus interfering with T-cell activation113. 
Subsequent studies from the same laboratory demonstra-
ted binding of Nef to the cytosolic tails of CD80 and 
CD86, triggering their endocytosis via Rac-based actin 
polymerization114. Furthermore, they also showed that 
Nef exploits the same pathways involved in normal MHC-
II recycling to target MHC-II to the lysosomal destina-
tion115. Additional studies from this group also point to 
the immunomodulatory properties of the viral accessory 
protein Vpu when they identified MHC-II invariant chain 
as a Vpu-interacting protein. They demonstrated that Vpu 
can down modulate the surface expression of mature MHC-
II molecules thus contributing to viral persistence by at-
tenuating immune responses during the viral infection116. 
 The vast majority of the publications on biologic and 
pathogenic properties of HIV-1 have originated from sub-
type B strains prevalent in North America and Europe. In 
contrast, little is known on subtype C strains prevalent in 
Africa and Asia and it is not understood why these strains 
are responsible for the large majority of the global epide-
mics. A collaborative effort between two research groups 
from Bangalore, southern India at the Jawaharlal Nehru 
Centre for Advanced Scientific Research (JNCASR) and 
the National Institute of Mental Health and Neurosci-
ences (NIMHANS) and one at the Albert Einstein Col-
lege of Medicine (AECOM), USA proposed that natural 
variation at position 31 of Tat of subtype C is correlated 
to the reported low incidence of HIV-associated dementia 
in India117–119 as this variation disrupted the monocyte 
chemokine nature of Tat120. This was perhaps the first 
demonstration of clade-specific molecular variations 
modulating viral biologic properties and possibly influ-
SPECIAL SECTION: BIOLOGY AND PATHOGENESIS OF VIRUSES 
 
CURRENT SCIENCE, VOL. 98, NO. 3, 10 FEBRUARY 2010 339
encing clinical manifestation121. Subsequent studies from 
Pankaj Seth’s laboratory at the National Brain Research 
Institute, Manesar, Haryana using human fetal central nerv-
ous system progenitor cell-derived astrocytes and neurons 
demonstrated clade-specific functional differences in Tat-
induced apoptosis in the neurons. The study identified 
significantly higher levels of neuron death when exposed 
to clade B Tat protein or DNA as compared to those of 
clade C122. Vinayaka Prasad’s laboratory at AECOM and 
other groups in the USA in collaboration with the 
JNCASR laboratory using the severe combined immune 
deficiency (SCID) mouse HIV encephalitis model and  
intracranial injection of macrophages infected with repre-
sentative viral strains demonstrated that clade C-induced 
fewer cognitive and memory errors compared to clade 
B123. A full-length infectious molecular clone of subtype 
C viral strain was isolated from a subject diagnosed with 
HIV-associated dementia at the JNCASR laboratory. 
Unlike the typical subtype C strains that use only CCR5, 
this molecular clone demonstrated expanded coreceptor 
requirement including the use of CXCR4 possibly under-
lying the cause of dementia in this subject124.  
 As suggested in many studies, HIV-1 Tat is considered 
to be a potential immunomodulator. Studies from Natio-
nal Centre for Cell Science, Pune demonstrated that  
coadministration of Tat as a genetic vaccine along with 
gp120 suppressed immune responses to the latter in mice 
and this immunosuppression was IL-10 mediated125. Ad-
ditional work from this group identified a phase-specific 
role of IL-12 in regulating the CTL response to gp120 in 
DNA immunization specifically in the priming of CD4+ 
T cells that provide help to CD8+ T cells. These data un-
derlie the importance of IL-12 for the priming of antigen-
specific T cells and its essential role in the induction of 
IFN-γ by T cells126. Previous work from Mitra’s group 
demonstrated a direct binding of Tat to the nuclear factor 
kappa B (NFκB) sites in the HIV-1 promoter, both in  
vitro and in vivo, thus not only providing a novel mole-
cular basis to explain TAR-independent transactivation of 
the viral promoter, but also pointing toward a potential 
mechanism of Tat-mediated modulation of cellular 
genes127. Work from the same laboratory pointed at the 
crucial role played by the heat shock protein 40 (Hsp40) 
in viral pathogenesis. Their demonstration that Nef not 
only interacted with Hsp40 but also induced the expres-
sion of Hsp40 in HIV-1 infected cells which alludes to 
the fact that Hsp40 is crucial for Nef-mediated enhance-
ment of viral gene expression and replication128. Work 
from this group also identified that viral infection causes 
apoptotic cell death by interfering with host cell energy 
generating machinery thus providing a novel molecular 
explanation for HIV-induced T cell depletion129,130. 
 In a series of publications, Mahalingam’s laboratory 
from southern India worked out the mechanism of nuclear 
export of SIV mediated by the accessory protein Vpx. 
They not only identified a novel import pathway for Vpx 
but also proved the significance of Vpx for the optimal 
virus replication in non-dividing cells such as macro-
phages131. In an extension of this work, they demon-
strated that the cellular MAPK signal transduction 
pathway regulated an early step in SIV infection and that 
the structural integrity of helical domains is critical for 
Vpx functions132. Subsequent analysis identified two dis-
tinct non-canonical nuclear localization signals in Vpx, 
one at the N-terminal domain interacting with importin 
alpha and the other at the C-terminal domain also inter-
acting with importin beta133. Furthermore, they have 
shown that Vpx is a nucleocytoplasmic shuttling protein 
and that the cellular Fyn kinase phosphorylates Vpx and 
regulates its export from nucleus134.  
Intervention strategies and technology  
development  
Despite the success of antiretroviral treatment, HIV/AIDS 
still poses a major public health problem globally. Deve-
lopment of viral resistance to drugs is common besides 
toxicity and pharmacokinetic differences between indivi-
duals. In the absence of an efficacious HIV-1 vaccine in 
the near future, other antiviral approaches are being acti-
vely considered along with the conventional antiretroviral 
therapy. These approaches at the global level have been 
reviewed extensively135.  
 Considering enormous potential of the virus to undergo 
rapid genetic variation, targeting host factors essential for 
virus proliferation is expected to offer a great advantage. 
Several efforts have focused on the coreceptor CCR5 
given that the individuals with CCR5 Δ32 mutation seem 
to lead a normal life. As demonstrated initially by Baner-
jea’s laboratory at the National Institute of Immuno-
logy105 and later confirmed by Mehra’s group at AIIMS107, 
CCR5 Δ32 mutation is quite rare in India. Banerjea’s 
group designed an anti-CCR5 hammerhead ribozyme and 
a 10–23 motif containing DNA-enzymes136. An indeed 
large number of strategies have also targeted various viral 
proteins in isolation or combinations. Catalytic RNAs 
with hammerhead catalytic motif and catalytic DNAs with 
the 10–23 or 03 8–17 motif have been exploited to knock 
off either HIV-1 coreceptors or other viral genes. Given 
the high variation rate, multiple regions of the HIV-1 
genes should be targeted, alternatively, a judicious com-
bination of viral as well as host factors must be used136. 
RNA aptamers have attracted a great deal of attention  
because they are generated via ligand evolution and bind 
ligands with high affinity. Greater understanding of the 
biology of HIV-1 replication also allowed the use of TAR 
and RRE decoys. These small RNA molecules can poten-
tially bind Tat and Rev proteins, and interfere with HIV-1 
replication. Thus, multiple HIV-1 interfering RNAs (Rzs, 
aptamers and siRNAs) can be engineered in the lentiviral 
vector under different promoters to provide long-term  
expression. Most of the lentivirus-based gene expression 
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systems have used HIV-1 backbone. In contrast, Robin 
Mukhopadhyay’s group in Mumbai has recently develo-
ped an HIV-2 based gene transfer system137. 
 Significant progress has been made in advancing the 
application of microbicides in women despite earlier fail-
ures. Talwar’s group from Delhi developed a novel poly-
herbal microbicide (Basant) with potent anti-HIV activity 
which is presently under clinical evaluation138.  
Vaccine research  
Although development of an AIDS vaccine continues to 
remain a research priority, few laboratories in India have 
been actively pursuing this goal. Practical problems,  
including the lack of a research primate model in the 
country, are a setback for launching serious vaccine  
development efforts in India. Vaccine research work in 
the Indian laboratories, therefore, is mainly restricted to 
immunization of small experimental animals without the 
necessary confirmation of the quality of the immune  
responses against virus challenge. Additionally, an even 
smaller number of efforts are currently in progress to 
evaluate a few clade C-based HIV vaccines in human 
clinical trials.  
 D. N. Rao’s group at AIIMS, Delhi evaluated peptide 
immunogens derived from Env along with the application 
of diverse novel adjuvants for inducing immune res-
ponses in mice139–143. Pradeep Seth’s laboratory from the 
same institute demonstrated antigen-specific immune res-
ponses in mice to HIV-1 gp160 delivered as a DNA  
vaccine144 or subtype C envelope and core proteins deli-
vered as recombinant modified Vaccinia Ankara (MVA)  
viruses145. Subsequently, using a DNA-MVA vaccine 
prime-boost formulations encoding env, gag and protease 
genes of Indian subtype C, they could elicit high levels of 
humoral and cell-mediated immune responses146. Varada-
rajan’s group at the Indian Institute of Science, Bangalore 
is actively pursuing the design of novel immunogen enti-
ties of gp120 to elicit neutralizing antibodies147,148. 
Ranga’s group at JNCASR, Bangalore has been develop-
ing Tat-based DNA vaccines for eliciting cell-mediated 
immune responses149,150. Recent work from this group 
identified a novel B-cell epitope in the cysteine-rich do-
main of Tat recognized only by the seropositive subjects 
but not by the natural antibodies present in the healthy 
controls151. Studies performed at NARI, Pune for neutra-
lizing antibody response in HIV seropositive subjects 
showed extensive cross-neutralization, suggesting pre-
sence of shared neutralization determinants among circu-
lating HIV-1 subtype C viruses in India152. A recent study 
from NARI has suggested that HIV-1 envelope regions 
other than the V3 domain may be involved in generating 
a neutralization response in HIV-1 subtype C infected  
individuals153.  
 In a randomized, multicentric, dose escalation phase I 
clinical trial, 30 HIV-uninfected healthy volunteers at 
NARI, Pune (and 50 volunteers in Europe) were recruited 
between February 2005 and January 2006 to evaluate a 
recombinant adeno-associated virus serotype-2 protein 
capsid (tgAAC09) vaccine, developed by the USA-based 
Targeted Genetics Corporation, encoding HIV-1 subtype 
C gag, protease, and part of reverse transcriptase genes. 
In the clinical trial that ended in December 2007, the vac-
cine was found to be safe and well-tolerated in human 
volunteers. Modest antigen-specific T cell responses were 
detected to Gag in the vaccinees154. Sekhar Chakrabarti’s 
laboratory at the National Institute of Cholera and Enteric 
Diseases, Kolkata constructed a recombinant MVA TBC-
M4 consisting of env, gag, tat, rev, nef and reverse tran-
scriptase genes derived from clade C of HIV-1. TBC-M4 
was evaluated in a second human clinical trial that started 
in January 2006, at the Tuberculosis Research Centre 
(TRC) in Chennai, under the auspices of the ICMR in 
collaboration with the International AIDS Vaccine Initia-
tive (IAVI). This two-year trial phase-I clinical trial  
involving 32 healthy men and women was found to be 
safe and elicited virus-specific immune responses in all 
the study participants although at moderate levels. A sci-
entific communication on the trial results is awaited. The 
momentum generated by the Chennai trial is leading to a 
third phase-I clinical trial to be evaluated simultaneously 
at two different sites in India TRC, Chennai and NARI, 
Pune. The third trial monitored by the ICMR, IAVI and 
the NACO is likely to enroll a larger number of partici-
pants. Considering the low quality immune responses 
generated in the Chennai clinical trial by TBC-M4, the 
new clinical trial will employ DNA priming using 
ADVAX DNA vaccine encoding HIV clade C env, gag, 
pol, nef and tat genes developed at the Aaron Diamond 
AIDS Research Center in New York City in collaboration 
with Rockefeller University and IAVI. This will be fol-
lowed by boosting with TBC-M4 to enhance the breadth 
and magnitude of the immune response. The TBC-
M4/ADVAX combination is also being evaluated in 32 
volunteers by St Stephen’s AIDS Trust in London in a 
different Phase-I clinical trial initiated in December 2008 
by the IAVI.  
Research priorities for the future 
With approximately 2.7–3 million infections, India har-
bours the second largest viral incidence of HIV in the 
world. In contrast to the original fears and projections, 
and despite the presence of the virus in the country for 
more than two decades, the viral infection has not crossed 
a danger limit. In many parts of the country, the incidence 
of the infection has remained below 1% level among gen-
eral population. With prevalent illiteracy and poverty, 
unorganized health care system, inadequate knowledge, 
rampant private blood bank industry, perennial drug traf-
ficking and extensive commercial sex work, it is rather 
surprising that HIV/AIDS has not become a more serious 
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medical hazard for India over the years. Furthermore, the 
viral incidence is even projected to have plateaued in  
India in the recent years although such a proposition must 
be carefully evaluated in the coming years because such 
an assumption could lead to complacency and neglect 
which could be harmful and counterproductive in the 
long run.  
 On one hand, the unique properties of HIV infection of 
India offer several interesting research questions of aca-
demic and medical importance whereas on the other,  
several practical considerations make it a daunting task to 
address many of these questions in an appropriate man-
ner. These difficulties, however, are not unique for the 
HIV research community alone but applicable broadly for 
other areas of research. Some of these practical issues 
have been summarized below. First, the small size of the 
research community makes it far inadequate to address 
several research questions of significance. This situation 
leads not only to the lack of a breadth of expertise but 
also to the absence of meaningful academic collaboration. 
Second, interaction between basic and clinical scientists 
is far from being significant. There is an urgent need to 
bridge this gap. Special grants must be offered by the 
government funding agencies to promote active research 
collaboration between basic research laboratories and the 
clinics including those in the private industry. Third, lack 
of skilled and trained personnel is seriously hampering 
research activity in the Indian laboratories. The driving 
force in most of the laboratories is the involvement of 
graduate students and project assistants. Absence of more 
experienced postdoctoral scientists and trained laboratory 
technicians is a serious setback and refractory to address 
research questions within a reasonable period of time. 
Fourth, lack of adequate funds and local technical re-
sources is a serious handicap. An average grant awarded 
by the Indian funding agencies is significantly small in 
comparison with international standards compelling re-
searchers to resort to multiple projects and thus spending 
significant amount of time on administrative and regula-
tory issues. Some of these problems could be sufficiently 
addressed by elevating the grant size to the international 
standards and by increasing the duration of the grants to a 
period of five years, instead of the present three years, 
with annual monitoring. Finally, not commensurate with 
the magnitude of the viral infection, India does not have 
adequate number of quality clinical cohorts. Thus most of 
the basic research is seriously compromised. Likewise, 
there are no high-containment experimental facilities in 
India for primate/virus challenge experiments seriously 
affecting vaccine development efforts.  
 As mentioned above, several characteristics of the HIV 
infection of India are unique and provide opportunities 
for meaningful research. The domination of subtype C is 
intriguing. The host restriction factors, including the 
MHC, cytokines, chemokines, miRNA, etc. that may favour 
the selective proliferation of specific viral subtypes must 
be identified. Given the size of the country and that the 
viral infection has spread to general populations in all the 
states and that the viral evolution is dynamic, independ-
ent foci of different subtypes or recombinants may be 
shaping up viral epidemics in different regions of the 
country. The finding of an indeed large number of  
recombinant forms from different parts of the country is 
quite alarming11. A recent study from Banerjea’s group 
reported the presence of more complex forms of recom-
binants in India17. A molecular epidemiological study on 
a larger number of samples from different parts of the 
country is urgently warranted to determine the real inci-
dence of the recombinant viruses of HIV-1 and to verify 
if new viral strains are in the process of emerging. The 
emergence of new recombinant strains could complicate 
the development of effective intervention strategies and 
their implementation. There have been few studies evalu-
ating natural history of HIV-1 in India. Several aspects of 
the natural history of the HIV infection must be subjected 
for extensive evaluation including the CD4 cell count dif-
ferences between the healthy and seropositive popula-
tions, the prognostic value of the CD4 cell dynamics for 
the disease progression, the average incubation periods 
for seroconversion from the time of infection, for the de-
velopment of AIDS from seroconversion and the median 
duration from AIDS to death. The validity of the CDC 
classification system for the Indian context needs a seri-
ous consideration. The influence of chronic infections in-
cluding the parasite load and malnutrition on the rate of 
disease progression must be examined. Individuals who 
might be protected against disease progression or capable 
of controlling the virus naturally must be identified and 
the host determinants underlying natural resistance must 
be evaluated. A nation-wide and coordinated campaign 
must be initiated to screen for individuals with broad 
level neutralizing antibodies. Such studies have a direct 
relevance to not only India but also to other countries 
where subtype C is the predominant viral strain. Now that 
first-line anti-retroviral therapy is being given out to peo-
ple through government-sponsored programmes and that 
second-line medicines are being rolled out for those who 
have developed resistance for the first-line drugs, the 
drug resistance in these populations must be examined. 
Prognostic markers that might predict drug failure as 
early as possible must be identified given that CD4 is not 
a good correlate for this purpose. This could be an impor-
tant area of research collaboration between the research 
and clinical groups. The nature of coreceptor requirement 
by subtype C strains and the near absence of coreceptor 
switch and its relevance to disease progression must be 
examined. The magnitude of genetic diversity of the virus 
is a formidable barrier for vaccine development. Efforts 
must be waged to develop multi-component vaccines to 
elicit broader, higher and long-lasting immune responses 
that offer cross-clade protection. As it is obvious that an 
effective vaccine will take sometime to come for human 
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use, serious efforts should also be initiated to rapidly  
develop an effective microbicide preparation.  
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